Cyclerion Therapeutics (CYCN) Accounts Payables (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Accounts Payables of $508000.0 for Q4 2025, up 30.26% year-over-year from $390000.0 in Q4 2024, and up 5.83% quarter-over-quarter from $480000.0 in Q3 2025.
Cyclerion Therapeutics (CYCN) Accounts Payables (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $508000.0 for Q4 2025.
- In Q4 2025, Accounts Payables rose 30.26% year-over-year to $508000.0; the TTM figure through Dec 2025 stood at $508000.0 (up 30.26% YoY), while the FY2025 annual figure was $508000.0, up 30.26% from the prior year.
- Accounts Payables for Q4 2025 stood at $508000.0, up from $480000.0 in the prior quarter.
- The five-year high for Accounts Payables was $3.9 million in Q1 2023, with the low at $304000.0 in Q3 2024.
- The 5-year median for Accounts Payables is $1.1 million (2021), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 130.05% in 2022, then tumbled 81.12% in 2024.
- Cyclerion Therapeutics' Accounts Payables stood at $1.8 million in 2021, then jumped by 62.47% to $3.0 million in 2022, then tumbled by 59.66% to $1.2 million in 2023, then sank by 67.45% to $390000.0 in 2024, then jumped by 30.26% to $508000.0 in 2025.
- Business Quant data shows CYCN's Accounts Payables at $508000.0 in Q4 2025, $480000.0 in Q3 2025, and $462000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | 508,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 508,000.00 |
| Sep 30, 2025 | 480,000.00 |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Sep 30, 2024 | 304,000.00 |
| Jun 30, 2024 | 651,000.00 |
| Mar 31, 2024 | 741,000.00 |
| Dec 31, 2023 | 1.20 Mn |
| Sep 30, 2023 | 814,000.00 |
| Jun 30, 2023 | 1.86 Mn |
| Mar 31, 2023 | 3.93 Mn |
| Dec 31, 2022 | 2.97 Mn |
| Sep 30, 2022 | 1.65 Mn |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | 2.52 Mn |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 1.17 Mn |
| Jun 30, 2021 | 1.39 Mn |
| Mar 31, 2021 | 1.10 Mn |